S

SAB Biotherapeutics Inc
NASDAQ:SABS

Watchlist Manager
SAB Biotherapeutics Inc
NASDAQ:SABS
Watchlist
Price: 3.99 USD 1.01% Market Closed
Market Cap: 190m USD

Intrinsic Value

The intrinsic value of one SABS stock under the Base Case scenario is 0.02 USD. Compared to the current market price of 3.99 USD, SAB Biotherapeutics Inc is Overvalued by 99%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SABS Intrinsic Value
0.02 USD
Overvaluation 99%
Intrinsic Value
Price
S
Base Case Scenario

Valuation History
SAB Biotherapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about SABS?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SABS valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for SAB Biotherapeutics Inc.

Explain Valuation
Compare SABS to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SABS?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
SAB Biotherapeutics Inc

Current Assets 113.3m
Cash & Short-Term Investments 110.9m
Receivables 559.9k
Other Current Assets 1.8m
Non-Current Assets 70.2m
Long-Term Investments 50.6m
PP&E 19.4m
Other Non-Current Assets 124k
Current Liabilities 10.8m
Accounts Payable 3m
Accrued Liabilities 7.7m
Other Current Liabilities 151k
Non-Current Liabilities 7.6m
Long-Term Debt 3.2m
Other Non-Current Liabilities 4.4m
Efficiency

Free Cash Flow Analysis
SAB Biotherapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
SAB Biotherapeutics Inc

Revenue
114.7k USD
Operating Expenses
-43.1m USD
Operating Income
-43m USD
Other Expenses
21.6m USD
Net Income
-21.4m USD
Fundamental Scores

SABS Profitability Score
Profitability Due Diligence

SAB Biotherapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

SAB Biotherapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

SABS Solvency Score
Solvency Due Diligence

SAB Biotherapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
62/100
Solvency
Score

SAB Biotherapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SABS Price Targets Summary
SAB Biotherapeutics Inc

Wall Street analysts forecast SABS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SABS is 9.01 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

Lowest
Price Target
5.05 USD
27% Upside
Average
Price Target
9.01 USD
126% Upside
Highest
Price Target
14.7 USD
268% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

SAB Biotherapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SABS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SABS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SABS stock?

The intrinsic value of one SABS stock under the Base Case scenario is 0.02 USD.

Is SABS stock undervalued or overvalued?

Compared to the current market price of 3.99 USD, SAB Biotherapeutics Inc is Overvalued by 99%.

Back to Top